Investor Presentaiton

9M 2022/23 Atos Medical impact on EBIT Atos Medical acquisition EBIT impact 3% 29% 29% 0% 28% 28% 1% 0% DKK 5 million (DKK 49m million related to Atos Medical integration costs) DKK 159 million DKK 86 million DKK 547 million EBIT margin after special items 9M 2022/23 Special items total¹ EBIT margin 9M 2022/23 before special items Atos Medical PPA amortisation EBIT 9M 2022/23 before special items & PPA amortisation Amortisation excl. Atos Medical PPA EBITA Depreciation before special items 1 Special items of DKK 5 million in 9M 2022/23. The special items include an income of DKK 244 million related to reversal of the provision regarding Atos Medical US billing compliance, DKK 200 million final provision in connection to MDL cases related to the use of mesh products in the US, and DKK 49 million related to integration costs for the Atos Medical acquisition. Around 25% of the purchase value of Atos Medical is treated as intangibles, amortized over 15 years. 68 32% EBITDA before special items Coloplast

View entire presentation